Posted by Michael Wonder on 06 Dec 2021
Theratechnologies submits supplemental biologics license application to FDA advancing development of IV push Trogarzo for patients living with HIV
6 December 2021 - sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results.
Theratechnologies is pleased to announce the submission of a supplemental biologics license application to the U.S. FDA for the Company’s intravenous push form of administration of Trogarzo.
